SalioGen Therapeutics utilizes its proprietary Gene Coding™ technology to integrate large DNA sequences at specific genomic locations without the use of viral vectors or double-stranded breaks. The company focuses on developing gene therapies for inherited disorders, including Stargardt disease and cystic fibrosis, to provide potentially curative treatment options for patients.
Funding
$152.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many genetic disorders lack effective treatments due to the challenges of safely and efficiently delivering therapeutic genes to specific locations within the genome. Traditional gene therapies often rely on viral vectors, which can trigger immune responses and insert genes randomly, or double-stranded breaks, which can cause unintended mutations.
Solution
SalioGen Therapeutics developed Gene Coding™, a technology for integrating large DNA sequences at precise genomic locations without viral vectors or double-stranded breaks. This approach enables targeted gene insertion for inherited disorders, offering the potential for curative treatments. The technology aims to overcome the limitations of conventional gene therapies by providing a safer and more precise method for delivering therapeutic genes.
Target Audience
The primary target audience includes patients with inherited disorders such as Stargardt disease and cystic fibrosis, as well as researchers and clinicians in the field of genetic medicine.
Features
- Gene Coding™ technology enables targeted integration of large DNA sequences.
- Avoids the use of viral vectors, reducing the risk of immune responses.
- Eliminates double-stranded breaks, minimizing the potential for off-target mutations.
- Potential applications include inherited retinal diseases, cystic fibrosis, and engineered CAR-T cells.